Literature DB >> 22271393

Bringing new players into the field: onco-pharmacovigilance in the era of cardio-oncology.

Adriana Albini, Francesco Donatelli, Douglas Noonan, Mario Milco D'Elios, Domenico Prisco.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22271393     DOI： 10.1007/s11739-012-0756-2

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  8 in total

Review 1.  Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  Intern Emerg Med       Date:  2011-12-13       Impact factor: 3.397

2.  Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.

Authors:  Bostjan Seruga; Lynn Sterling; Lisa Wang; Ian F Tannock
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

3.  Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.

Authors:  Adriana Albini; Eugenio Cesana; Francesco Donatelli; Rosaria Cammarota; Eraldo O Bucci; Massimo Baravelli; Claudio Anzà; Douglas M Noonan
Journal:  Future Cardiol       Date:  2011-09

4.  Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1).

Authors:  Sergio Siragusa; Ugo Armani; Monica Carpenedo; Anna Falanga; Fabio Fulfaro; Davide Imberti; Renzo Laurora; Angelo Claudio Molinari; Domenico Prisco; Mauro Silingardi; Melina Verso; Adriana Visonà
Journal:  Thromb Res       Date:  2011-10-02       Impact factor: 3.944

5.  Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort.

Authors:  M Veglio; G Bruno; M Borra; G Macchia; G Bargero; N D'Errico; G F Pagano; P Cavallo-Perin
Journal:  J Intern Med       Date:  2002-04       Impact factor: 8.989

6.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

Review 7.  Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use.

Authors:  Alberto Dolci; Roberto Dominici; Daniela Cardinale; Maria T Sandri; Mauro Panteghini
Journal:  Am J Clin Pathol       Date:  2008-11       Impact factor: 2.493

Review 8.  Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.

Authors:  Adriana Albini; Giuseppina Pennesi; Francesco Donatelli; Rosaria Cammarota; Silvio De Flora; Douglas M Noonan
Journal:  J Natl Cancer Inst       Date:  2009-12-10       Impact factor: 13.506
  8 in total
  3 in total

1.  Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology.

Authors:  Adriana Albini; Francesco Donatelli; Chiara Focaccetti; Mario Milco D'Elios; Douglas M Noonan
Journal:  Intern Emerg Med       Date:  2012-09-02       Impact factor: 3.397

2.  Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study.

Authors:  Sewunet Admasu Belachew; Daniel Asfaw Erku; Abebe Basazn Mekuria; Begashaw Melaku Gebresillassie
Journal:  Drug Healthc Patient Saf       Date:  2016-12-08

3.  Bibliometric Analysis of the Results of Cardio-Oncology Research.

Authors:  Kangkang Wei; Jiangquan Liao; Jiangmeng Chang; Xiaoqiong Zhang; Ming Chen; Jinhang Du
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-13       Impact factor: 2.629
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.